COMP <GO>
GRFS vs COGT // 10Y YIELD & FRED MACRO BETA
Grifols S.A. (NASDAQ) VS. Cogent Biosciences Inc. (NASDAQ) • 15-METRIC TALLY: GRFS 2
— COGT 0
■ METRIC PARITY
LAST: $8.51 (+5.06%) • MKT CAP: $5.57B
macro-sensitivity
—
LAST: $29.73 (-4.16%) • MKT CAP: $5.38B
macro-sensitivity
1.05
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GRFS VS. COGT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GRFS | COGT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -35.00% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -4.80% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -21.50% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -21.20% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 22.00% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 10.84 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 5/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 66.8 | 47.2 | +19.60 | GRFS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | — | 1.05 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 22.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.57B | $5.38B | $186.4M | GRFS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GRFS REV | COGT REV | GRFS GROSS % | COGT GROSS % | GRFS FCF | COGT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $933.4M | — | — | — | -$266.0M |
| FY 2024 | — | $772.6M | — | — | — | -$208.4M |
| FY 2023 | — | $582.8M | — | — | — | -$153.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GRFS // BETA —
COGT // BETA 1.05